Cite
HARVARD Citation
Butzkueven, H. et al. (2021). No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic advances in neurological disorders. p. . [Online].